Biomarkers in Post-Menopausal Women Receiving Flaxseed
Status: | Completed |
---|---|
Conditions: | Healthy Studies |
Therapuetic Areas: | Other |
Healthy: | No |
Age Range: | 45 - 80 |
Updated: | 1/11/2018 |
Start Date: | December 14, 2012 |
End Date: | June 8, 2017 |
A Pilot Study of the Flaxseed Effects on Hormones and Lignans: Role of Race, Genes, and Gut Microbiome
This randomized clinical trial studies biomarkers in post-menopausal women receiving
flaxseed. Studying samples of blood, urine, and feces in the laboratory from participants
receiving flaxseed may help doctors understand the effects of flaxseed on biomarkers.
flaxseed. Studying samples of blood, urine, and feces in the laboratory from participants
receiving flaxseed may help doctors understand the effects of flaxseed on biomarkers.
PRIMARY OBJECTIVES:
I. To determine associations between the composition of the gut bacterial communities and
baseline levels of the mammalian lignans and steroid hormones.
II. To determine how variation in gut microbial community composition and in steroid hormone
and xenobiotic metabolizing genes affects the metabolism of mammalian lignans and steroid
hormones after exposure to a lignan-rich food (flaxseed).
III. To determine how these associations differ by race (i.e., African American and European
American women).
OUTLINE: Participants are randomized to 1 of 2 treatment groups.
GROUP I: Participants receive flaxseed orally (PO) daily for 6 weeks. After a usual diet
"washout" period of 8 weeks, patients crossover to Group II.
GROUP II: Participants maintain a usual diet for 6 weeks. After a usual diet "washout" period
of 8 weeks, patients crossover to Group I.
After completion of study treatment, participants are followed up for 30 days.
I. To determine associations between the composition of the gut bacterial communities and
baseline levels of the mammalian lignans and steroid hormones.
II. To determine how variation in gut microbial community composition and in steroid hormone
and xenobiotic metabolizing genes affects the metabolism of mammalian lignans and steroid
hormones after exposure to a lignan-rich food (flaxseed).
III. To determine how these associations differ by race (i.e., African American and European
American women).
OUTLINE: Participants are randomized to 1 of 2 treatment groups.
GROUP I: Participants receive flaxseed orally (PO) daily for 6 weeks. After a usual diet
"washout" period of 8 weeks, patients crossover to Group II.
GROUP II: Participants maintain a usual diet for 6 weeks. After a usual diet "washout" period
of 8 weeks, patients crossover to Group I.
After completion of study treatment, participants are followed up for 30 days.
Inclusion Criteria:
- Participant must understand the investigational nature of this study and sign an
Independent Ethics Committee/Institutional Review Board approved written informed
consent form prior to receiving any study related procedure
- Participant must be a non-Hispanic white or non-Hispanic black (self-reported race)
woman 45 to 80 years of age and postmenopausal; postmenopausal will be defined as no
menstrual cycle in the past 12 months; women with a hysterectomy but with intact
ovaries will be included if aged >= 55 years
- Willingness to comply with the requirements of the study
Exclusion Criteria:
- Unwilling or unable to follow protocol requirements
- Self-reported race other than non-Hispanic white or non-Hispanic black
- Use, in the 2 months prior to week 1 visit, of antibiotics, hormone replacement
therapy, nonprescription hormones or herbal supplements for menopausal symptoms, or
flaxseed supplements
- Nut or seed allergy
- Self-reported inflammatory bowel disease
- Gastric bypass
- Use of thyroid replacement medication (Synthroid or similar) for < 1 year
- Any condition which in the investigator's opinion deems the participant an unsuitable
candidate to receive flaxseed
- Chemotherapy/radiation within the past year
- Body weight greater than 400 pounds (limit of Tanita scale)
We found this trial at
1
site
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Susan McCann
Phone: 877-275-7724
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials